In a welcome move, Kura Oncology stock saw its Relative Strength Rating improve from 69 to 75 on Wednesday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
History shows that the best stocks often have an 80 or better RS Rating in the early stages of their moves. See if Kura Oncology can continue to show renewed price strength and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Is Kura Oncology Stock A Buy?
Kura Oncology stock is currently trading in a consolidation. On the bright side, the biotech stock retook its 50- and 200-day moving average. Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to offer and clear an appropriate buy point. It's best to wait for the stock market outlook to turn up.
Taking a look at revenue and profit performance, the biotech company has posted four quarters of increasing earnings growth. Top line growth has not followed the same trajectory, coming in at 0% in the most recent report. The company is expected to report its next quarterly numbers on or around Nov. 4.
Kura Oncology stock holds the No. 136 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab and Vertex Pharmaceuticals are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
